How Is Microsatellite Instability (MSI) Treated? Effective Immunotherapy Options Explained
Learn how MSI-high cancers are treated with immunotherapy like Pembrolizumab and Nivolumab. Personalized cancer treatment insights.
0 views
Microsatellite instability (MSI) can be treated using immunotherapy. Drugs like Pembrolizumab and Nivolumab are often effective for MSI-high cancers, which include colorectal, endometrial, and other types. These medications help boost the body's immune response against cancer cells. However, treatment plans should be personalized, so consulting with a healthcare provider for tailored advice is essential.
FAQs & Answers
- What is microsatellite instability (MSI) in cancer? Microsatellite instability is a condition of genetic hypermutability that occurs in some cancers due to defects in DNA mismatch repair, leading to MSI-high tumors.
- Which immunotherapy drugs are commonly used to treat MSI-high cancers? Pembrolizumab and Nivolumab are immunotherapy drugs often used to treat MSI-high cancers by enhancing the immune system’s ability to target cancer cells.
- What types of cancers typically show microsatellite instability? MSI-high status is commonly found in colorectal cancer, endometrial cancer, and some other cancer types.
- Why is personalized treatment important for MSI cancers? Because each patient’s cancer may respond differently, personalized treatment ensures the best therapeutic strategy based on individual tumor characteristics and health status.